Impact of Lycium barbarum polysaccharide on apoptosis in Mycoplasma-infected splenic lymphocytes
Purpose: To evaluate the effect of Lycium barbarum polysaccharide (LBP) on apoptosis in Mycoplasma-infected splenic lymphocytes (SLs), and the underlying mechanisms.
Methods: SLs isolated from C57BL/6J mice were infected with Mycoplasma. The infected SLs were administered at different concentrations of LBP for 4 h, and the proportions of apoptotic cells and levels of relative reactive oxygen species (ROS) were determined by flow cytometry. The expressions of proapoptotic genes and endogenous antioxidant enzymes were investigated by real-time polymerase chain reaction (RT-PCR) and Western blotting.
Results: LBP treatment produced dose-dependent reductions in apoptotic ratio and intracellular ROS levels of SLs (p < 0.05). In addition, the expressions of pro-apoptotic genes were decreased by LBP treatment with respect to mRNA and protein levels (p < 0.05). In contrast, mRNA and protein levels of anti-apoptotic factor Bcl-2 were significantly increased in a dose-dependent manner (p < 0.05). Furthermore, RT-PCR and Western blot results demonstrated that the expression levels of mRNA and proteins in Nrf2, HO-1 and NQO1 were up-regulated by Mycoplasma infection (p < 0.01), and further increased by LBP treatment (p < 0.05).
Conclusion: LBP exerts a hyperactive antioxidant response encoded by Nrf2 to protect SLs from apoptosis induced by ROS-related oxidative damage after Mycoplasma infection. These results suggest that LBP may serve as a beneficial and dietary anti-Mycoplasma and anti-apoptotic agent.
Keywords: Lycium barbarum polysaccharide, Splenic lymphocytes, ROS, Caspase-3, Bax, Nrf2
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.